Open in App
  • U.S.
  • Election
  • Newsletter
  • BioMed Central

    Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain

    By Ruth Gil-Prieto,

    2 days ago
    Comments / 0
    Add a Comment
    YOU MAY ALSO LIKE
    Most Popular newsMost Popular

    Comments / 0